MayMag Biologics Corp Expands Domestic cGMP Co-Manufacturing Capacity in Texas to Support SAM.gov Federal Prime Contractors

 MayMag Biologics Corp Expands Domestic cGMP Co-Manufacturing Capacity in Texas to Support SAM.gov Federal Prime Contractors

FDA-registered Section 506(e) outsourcing facility and U.S. CDMO offers audit-ready sterile injectable biologics and Rx/OTC oral solid dosage manufacturing to strengthen domestic federal medical supply chains.

DALLAS, TX — November 2026 — MayMag Biologics Corp (formerly Tirzepatide Pharma), an FDA-registered Section 506(e) outsourcing facility and U.S.-based Contract Development and Manufacturing Organization (CDMO), announced today the expansion of its domestic co-manufacturing and fill-finish partnerships tailored specifically for SAM.gov prime contract awardees. Operating dual cGMP-certified manufacturing facilities in Dallas and Garland, Texas, MayMag Biologics provides federal prime contractors with a compliant, onshore partner for sterile injectable biologics and prescription (Rx) and over-the-counter (OTC) oral solid dosages.

As federal agencies—including the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), Department of Defense (DoD), and Department of Veterans Affairs (VA)—enforce heightened scrutiny over domestic supply chain resiliency and country-of-origin certifications, prime contractors face increasing pressure to eliminate offshore manufacturing dependencies. MayMag Biologics’ 100% U.S.-based footprint enables prime awardees to meet strict Buy American Act (BAA), Trade Agreements Act (TAA), and Federal Acquisition Regulation (FAR) domestic sourcing mandates while maintaining rapid, scalable production.

"Federal prime contractors managing mission-critical health and defense supply chains cannot afford offshore bottlenecks or regulatory compliance gaps," said IjYahu Raphe, Founder and Principal Inventor at MayMag Biologics Corp. "By consolidating sterile injectable biologics and high-volume Rx and OTC oral solid dose production across our Dallas and Garland cGMP facilities, we give prime awardees an audit-ready, 100% domestic co-manufacturing partner engineered for speed, traceability, and uncompromising quality."

Comprehensive Dual-Modality Co-Manufacturing Capabilities

MayMag Biologics supports federal subcontracting requirements across multiple primary procurement classifications—including NAICS 325414 (Biological Product Manufacturing), 325412 (Pharmaceutical Preparation Manufacturing), 325411 (Medicinal and Botanical Manufacturing), 339112 (Surgical and Medical Instrument Manufacturing), and PSC 6505 (Drugs and Biologicals)—with end-to-end technical execution:

  • Sterile Injectable Biologics & Fill-Finish: End-to-end solid-phase peptide synthesis (including GLP-1 and GIP/GLP-1 agonists), biosimilar insulin analog formulation, large-volume sterile injectable fill-finish, prefilled syringes, multi-dose cartridges, auto-injection pen assembly (such as rheumatoid arthritis and epinephrine autoinjectors), sterile Bacteriostatic Water for Injection (BWFI), and Metered-Dose/Dry Powder Inhalers (MDI/DPI).

  • Oral Solid Dosages (Rx & OTC): Scalable cGMP compounding, granulation, tablet compression, capsule filling, and blister or bottle packaging designed for rapid technology transfer, emergency stockpile replenishment, and commercial federal distribution.

  • In-House Compendial Analytical & Lot-Release Testing: Full quality control laboratories executing USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter, HPLC potency assays, and 12-week ICH accelerated stability studies on every batch with zero historical extrapolation.

Audit-Ready Regulatory & Quality Compliance

Every production run at MayMag Biologics is governed by strict adherence to FDA 21 CFR Parts 210–211, ISO 13485, and USP <797> and <800> standards, alongside full Drug Supply Chain Security Act (DSCSA) serialization readiness. Recent cleanroom modernization and equipment qualification across the company’s dual Texas facilities allow prime contractors to seamlessly scale from pilot and clinical-stage response batches to high-volume commercial fulfillment.

Federal prime contractors, supplier diversity managers, and procurement officers seeking a vetted domestic biologics or oral solid dosage co-manufacturer can request MayMag Biologics’ Federal Capability Statement or initiate a technical capability review by contacting the company’s government contracting team directly.

About MayMag Biologics Corp

Headquartered in the Dallas–Fort Worth metroplex with cGMP-certified facilities in Dallas and Garland, Texas, MayMag Biologics Corp is an FDA-registered Section 506(e) outsourcing facility and full-service Contract Development and Manufacturing Organization (CDMO). Specializing in sterile injectable biologics, peptide synthesis, combination delivery devices, and prescription/OTC oral solid dosages, MayMag Biologics delivers compliant, end-to-end domestic pharmaceutical manufacturing and analytical testing for commercial and federal supply chains.

Media & Federal Contracting Contact:

mmb@maymagbiologics.com 

esr@maymagbiologics.com



Comments

Popular posts from this blog

FDA approved Biosimilar Injectable Biologics Contract Manufacturer in USA-MayMag Biologics

Mastering Parenteral Delivery: Technical Excellence in GLP-1 and Insulin Device CDMO Services

Scaling Parenteral Drug Delivery: Why Next-Gen Biologics Demand a Specialized Device CDMO